Home › Compound Library › Inositol (Myo-Inositol)

Inositol (Myo-Inositol)

Amino Acidoral · inferred

Carbocyclic sugar and second messenger precursor. Myo-inositol is the predominant form, critical for phosphatidylinositol signaling (IP3/DAG pathway). At high doses (12-18g/day), effective for panic disorder and OCD, comparable to SSRIs in some trials. Also used for PCOS (improves insulin sensitivity and ovulation at 2-4g/day) and metabolic syndrome. Well-tolerated; GI upset at high doses. Not a true vitamin but sometimes called vitamin B8.

Projected serum levels — 2k mg, once daily

Inositol (Myo-Inositol)
Inositol (Myo-Inositol) modeled serum levels, 2k mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 250 500 750 1k Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 2k mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 891 mg, trough ≈ 11.8 mg body load. Population-based estimate over 15 days for a 2k mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Amino Acid
Route modeled
Oral
Model confidence
inferred
Half-life
3 h
Common dose
2k mg
Suggested maximum
18k mg/day
Reference dose range
1k–18k mg (single dose)
Suggested cadence
once daily
Validated against
2k mg oral — Cmax 72 mg/L at 3 h

Research behind this entry

  1. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder Palatnik A et al. · Journal of Clinical Psychopharmacology, 2001 DOI

    Crossover RCT finding inositol 18g/day comparable to fluvoxamine 150 mg/day for panic disorder, with fewer side effects and no withdrawal symptoms upon discontinuation.

  2. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials Unfer V et al. · Endocrine Connections, 2017 DOI

    Meta-analysis of 10 RCTs confirming myo-inositol 2-4g/day improves ovulation rate, menstrual regularity, and insulin sensitivity in PCOS women, with efficacy approaching metformin for some outcomes.

  3. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. Palatnik A, Frolov K, Fux M, Benjamin J · Journal of clinical psychopharmacology, 2001 DOI

    This citation reports a human clinical study involving Inositol (Myo-Inositol). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.